When a stock has a #$%$ load of assets you don't expect it to stay down here. It lost 10% a day many times coming down from the heavens. It just sold part of them and raised cash. 80% of this stock is insider and institutionally owned . They have suffered the most. Environmental solutions is not dead in the USA and neither is this stock. The only bizarre thing is nobody knows about it. Enjoy the ride .
It can only go down so much. The company has value and will make money again. MOST oil stocks have found the bottom and quit fall the last time oil went down. We are very close and should see a lot better days. Its time to buy the stocks.
Sentiment: Strong Buy
This only gets better as the industry is very close to a bottom. The cycle looks to be up. I am not going to be on the side lines waving goodbye to this all the way to 10 dollars.
Download this Press Release (PDF 70 KB)
FORT WORTH, Texas--(BUSINESS WIRE)-- Approach Resources Inc. (NASDAQ:AREX) today reported estimated fourth quarter and full-year 2014 production and reserves.
Fourth quarter production was 15.1 MBoe/d, a 34% increase over the prior-year quarter
Full-year 2014 production was 5,049 MBoe, a 47% increase over the prior year
Oil production was 2,024 MBbls, a 40% increase over the prior year
Oil production represented 40% of total production for full-year 2014
Drilled 68 horizontal wells and placed 64 horizontal wells on production
2014 capital expenditures of $393.5 million
Proved Reserves Highlights
Year-end 2014 proved reserves grew to 146.2 MMBoe, a 27% increase over the prior year
PV-10 (non-GAAP) was $1.4 billion, a 25% increase over the prior year
Ross Craft , Approach’s Chairman and CEO commented, “At the beginning of 2014 we set an ambitious goal of achieving a 40% annual production growth rate, while maintaining one of the lowest drilling and completion cost structures in the Permian Basin. Now with 12 months behind us, I am very pleased with the operational performance of our team. Not only were we able to beat our original production goal and deliver a 47% growth in production, but even more importantly, we were able to do that while controlling our capital costs, which came in below our original $400 million budget.
Looking ahead to 2015, our industry is presented with a different set of challenges, given the significant change in commodity prices. We continue to conservatively manage our balance sheet, and we remain flexible on our capital spending budget, particularly as we take proactive steps to further reduce our cost structure and enhance drilling economics. Most importantly, we have no near-term debt maturities, and our liquidity position is strong, providing the ability to weather a prolonged downturn in commodity prices and to take advantage of opportunities that may become available.”
Estimated Fourth Quarter and Full-Year 2014 Production
Estimated fourth quarter 2014 production totaled 1,390 MBoe (15.1 MBoe/d), a 34% increase over fourth quarter 2013 and a 6.4% increase over third quarter 2014. Estimated oil production for fourth quarter 2014 increased 14% compared to fourth quarter 2013 and 7.1% from third quarter 2014.
Estimated full-year 2014 production totaled 5,049 MBoe (13.8 MBoe/d), a 47% increase over 2013. Oil production for 2014 increased 40% compared to 2013.
In the last 10 years the stock has spiked up over 400% 4 times. That's pretty good odds of making a killing in the next 18 months. BUY BY!
Most don't understand IBIO.... They have different treatments and cures. The pipelines does include cures and solutions for diseases. The best thing the company has going for it is the technology to work with other companies pipelines. ONCE a companies sees the potential to help their solutions be massed produces in quantity , cheap and reliable the company will be bought. Just the platform is going to open eyes. I must laugh at the shorts that do not understand the potential for mapp, ICOn, Amgen, JAZZ and others they see as IBIOs competition actually be their best customers. How is your technology faster to produce than other plant-based protein companies?
The iBioLaunch™ technology is a third generation plant-based protein expression technology. The first generation, which some companies still use, relies on transgenic (sometimes called GMO plants, a process that is very slow and relatively low in yield. The second generation, also still used by some companies, is based on transient virus-delivery of genes into non-transgenic plants. While this technology works rapidly, there are yield constraints and target product size limitations that limit its applicability. iBioLaunch™ technology harnesses the combined biological features of bacterial, viral and plant biology to achieve the speed of transient production without the yield and size limitations of older technology. Because iBio’s technology is proprietary and protected by issued and pending patents, it is not available to companies using older or publicly available technology except through commercial agreements with iBio. Transgenic plants
Transgenic plants are plants that have been genetically engineered, a breeding approach that uses recombinant DNA techniques to create plants with new characteristics. They are identified as a class of genetically modified organism (GMO). Stable cell lines offer consistent product quality, but clone (grow) the same plant over and over.
With transient, the induction of major biological or therapeutic effects on the basis of "hit-and-run" mechanisms. With transient they deliver into the plant, the outside intruders , the plant identifies the intruders and make the desired variety of proteins – including antibodies, biochemical targets of interest, vaccines, viral vectors and virus-like particles – can be rapidly expressed. 1st generation, transgenic –plants are genetically engineered – slow process… . 2nd Generation- is based on transient virus-delivery of genes into non-transgenic plants,( non-engineered plant) . You target the whole plant and fundamentally alter a host cell’s DNA changing the plant …… 3rd Generation- there is no need to isolate and expand rare, high-producing cell clones to production level. A gene of interest can be cloned and inserted into the iBioLaunch vectors and be ready for production at scale within a month’s time. Using the plant to extract antibodies many times, (optimizing). In addition, the transient nature of the expression system allows the accumulation of massive amounts of desired protein over a four- to seven-day period, after which time purification can begin.
there is a lot of waist products and it needs a infrastructure clean up. Up front is expensive. Once developed and agreed upon the true cost develops. This company is making a niche that can do well. 38% shorts could get a real surprise.
IBIO is the future of proteins and antibodies. The next press could be a buy out. Its to cheap for the new developments in biotechnology.
you will never see Walker pres. . He is the example of what is wrong with the TEA party and cold republicanism. You are to stupid to know it.
the world is full of stupid people are still looking for inflation and birth certificates.
no he want to attack the middle class and unions. I WILL FIGHT him forever. HE is the enemy.!!!!!!!!!!!!!!!
he would sell his Mamma for a few votes. Try to run the country by killing Unions. He is an IDIOT . period. No smart president has ever tried to damage the middle class more. TRASH!!!!!!!!!!!!!!!!!!!!
• Seasonal and H1N1 Influenza Vaccines. The company believes the company's technology is applicable to target vaccines directed against seasonal influenza virus strains. Its vaccine candidates have shown significant promise in preclinical efficacy studies in ferrets (the preferred animal model for testing influenza products). In an evaluation of three vaccine candidate formulations in groups of eight ferrets each along with both positive and negative controls, no adverse events were seen in any animals receiving iBio's vaccine candidates. Only one animal receiving one of the company's vaccine candidates showed any measurable virus shedding which is an important measure of vaccine effectiveness. These results were as good as the results obtained with positive control animals. The immune responses and protective immunity induced by its vaccine candidates in these animal tests are equivalent to results expected from this type of test to indicate the probability of effectiveness in human subjects. More detail on these tests is available in the scientific paper published in 2008 in the journal Influenza and Other Respiratory Viruses, Volume 2, pages 33-40.
• I believe iBio's technology is applicable to H1N1 swine-like influenza strains and other seasonal strains, and iBio Inc. expects to modify its product development plans to incorporate H1N1 antigens into any new seasonal vaccine formulation IBIO advance to clinical testing.
• Unlike the most common method of producing vaccines against influenza, its process does not rely on chicken eggs and does not require work with whole influenza viruses. Rather, the company produces subunit vaccines that are composed of only parts of the protein components of the disease-causing viruses. I believe the company's subunit vaccines are promising for prevention of influenza infection in humans because they have been demonstrated to prevent influenza infections in ferrets. The ferret is the animal species that is typically used to evaluate a candidate influenza vaccine in laboratory tests before it is tested on humans.
• Pandemic Avian Influenza Vaccine. Through FhCMB and their funding from the Gates Foundation, iBio Inc. are developing vaccine candidates targeting highly pathogenic avian influenza (H5N1) viruses based upon the iBioLaunch(tm) platform. These candidates have demonstrated immunogenicity and have been successfully tested in mice and ferrets for protective efficacy. Like iBio's candidate vaccines for seasonal influenza, its candidate vaccines for avian influenza are subunit vaccines. Thus, the company does not need to culture the intact avian influenza virus in order to produce the company's candidate vaccines. The Gates Foundation has committed significant funding to FhCMB for preclinical development and a Phase 1 human clinical trial of this pandemic influenza vaccine candidate using its technology. The company's longer term goal is to develop a combined vaccine effective for preventing both seasonal and pandemic influenza infections.
• Therapeutic Vaccine for Human Papilloma Virus. It has commercial rights to vaccine candidates developed pursuant to its business structure based on fusing a protein component of HPV called the E7 antigen, to the LicKM protein of the bacterium Clostridium thermocellum. Several of these candidate vaccine formulations have demonstrated sufficient immune stimulation and protection from disease in mouse experiments to justify further investment in its development as a potential human therapeutic product. In experimental tests in mice, with each formulation administered to ten mice, some candidates protected all of the mice from the growth of tumors caused by the HPV virus. Additional detail on these experiments was published in 2007 and 2009 in the scientific jiBio'snal Vaccine, 2007; 25(16):3018-3021 and 2009; 27(25-26):3395-3397.
• Biodefense Products. The company has commercial rights to an oral anthrax booster vaccine candidate developed by FhCMB in collaboration with the Naval Medical Research Center (NMRC). Animal tests have demonstrated safety and efficacy of this product candidate. IBio Inc. also have commercial rights to candidate plague vaccines that FhCMB has demonstrated to be effective in non-human primate tests in which four groups of two monkeys each were inoculated and then challenged with plague infection. Detailed results of these experiments were published in 2007 in the scientific journal Vaccine, 2007 Apr 20; 25(16):3014-7.
• As previously indicated, the U.S. Department of Defense ("DoD") has also provided funding to FhCMB for refinement of its technology platform and for preclinical and clinical studies for an anthrax-plague combination vaccine and for an H1N1 influenza vaccine project. Specifically, a study in non-human primates demonstrated 100% protection against challenge with anthrax spores, and dose de-escalation studies are currently underway. To date, FhCMB has received funding and funding commitments for these projects totaling approximately $37 million. This funding is similarly beneficial to us because the company have retained the commercial rights to any technology improvements resulting from those projects.
• Vaccines for Developing Markets. Funding for developing-world products comes primarily from FhCMB's collaborators, especially the Gates Foundation, and supplements the research and development payments that the company make to FhCMB to advance and expand the technology to which IBIO have exclusive commercial rights. This supplemental funding provides significant benefits in technology optimization and is synergistic with iBio's product development programs. Through these developing world programs positive preclinical immunogenicity and efficacy results have been obtained for vaccines for HPV, trypanosomiasis and malaria.